Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 49, Issue 5, 2001, Pages 1297-1303

  Lederman, G S ^a   Cavanagh, W ^b   Albert, P S ^a   Israeli, R ^a   Lessing, J ^a   Savino, M ^a   Volpicella, F ^a  

^a STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^b Seattle Prostate Institute   (United States)

Author keywords

103P; 125I; Brachytherapy; Prostate Cancer

Indexed keywords

DIAGNOSIS; DISEASES; PATIENT TREATMENT; TUMORS;

RELAPSE-FREE SURVIVALS;

RADIOTHERAPY;

IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

BEAM THERAPY; BIOCHEMISTRY; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; CONFERENCE PAPER; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; ORGANIZATION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT FAILURE;

ANALYSIS OF VARIANCE; BRACHYTHERAPY; COHORT STUDIES; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; PALLADIUM; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 0035312444     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)01442-5     Document Type: Conference Paper

References (20)

1. Palladium-103 brachytherapy for prostate carcinoma
2. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma [see comments]
3. Should brachytherapy be considered a therapeutic option in localized prostate cancer?
4. Palladium-103 brachytherapy for clinical T1/T2 prostate carcinomas (Astr. 1011)
5. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer
6. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer
7. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer [see comments]
8. The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy
9. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation
10. Radical radiation therapy in the management of prostatic adenocarcinoma; The initial prostate specific antigen value as a predictor of treatment outcome
11. Nonparametric estimation for incomplete observations
12. Regression models and life tables
13. Cancer statistics, 1995
14. Optimal radiotherapy for prostate cancer; predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models
15. The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy
16. Transient elevation of serum prostate-specific antigen following 125I/103Pd brachytherapy for localized prostate cancer
17. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control
18. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy
19. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer